Brimnes Niels
Aarhus University, Institute of History and Area Studies, Building 1410, Ndr. Ringgade, Aarhus 8000, Denmark.
Soc Sci Med. 2008 Sep;67(5):863-73. doi: 10.1016/j.socscimed.2008.05.016. Epub 2008 Jun 21.
Mass vaccination with BCG against tuberculosis has been one of the major health interventions of WHO since the Second World War. This article traces the history of the controversial BCG vaccine from its adoption by WHO in 1948 up to 1983. In 1948, there was no clear scientific evidence to support the vaccine, and its adoption by WHO seems to have been urged by the existence of the UNICEF funded 'International Tuberculosis Campaign' and a fear of a threatening global epidemic. Moreover, BCG fitted well with the post Second World War perception of public health interventions. The vaccine was not systematically reviewed by WHO until 1959, and this review appears to have been biased in favour of the vaccine. In 1979 the results from the South Indian Chingleput trial, which showed no protective effect of BCG against pulmonary tuberculosis in adults, prompted WHO to change the arguments for recommending the vaccine. Since 1983 BCG has been recommended with specific reference to its protective effect against severe forms of childhood tuberculosis. The story of the BCG vaccine and WHO is a story of medical uncertainty, institutional inertia, strategic obduracy, and not least, hope.
自第二次世界大战以来,大规模接种卡介苗预防结核病一直是世界卫生组织的主要卫生干预措施之一。本文追溯了备受争议的卡介苗从1948年被世界卫生组织采用到1983年的历史。1948年,没有明确的科学证据支持该疫苗,世界卫生组织采用它似乎是受到了联合国儿童基金会资助的“国际结核病防治运动”的推动以及对一场威胁全球的流行病的担忧。此外,卡介苗与二战后对公共卫生干预措施的认知相契合。直到1959年世界卫生组织才对该疫苗进行系统审查,而这次审查似乎存在偏袒该疫苗的倾向。1979年,南印度钦格洛普试验的结果表明卡介苗对成人肺结核没有保护作用,促使世界卫生组织改变了推荐该疫苗的理由。自1983年以来,推荐卡介苗时特别提到了其对儿童严重结核病形式的保护作用。卡介苗疫苗和世界卫生组织的故事是一个关于医学不确定性、机构惰性、战略固执,以及最重要的,希望的故事。